Skip to main content

IMAB

Stock

IMAB

Stock
Health Care
Biotechnology

Performance overview

IMAB Price
Price Chart

Forward-looking statistics

Beta
1.03
Risk
70.43%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.

Company info

SectorHealth Care
IndustryBiotechnology
Employees229
Market cap$152.1M

Fundamentals

Enterprise value$289.6M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity1.86

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.55
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth-4.3
Credit+5.3
Liquidity-0.8
Inflation-5.9
Commodities+0.2
Interest Rates-3.3

Valuation

Dividend yield0.00%
PEG Ratio-1.46
Price to sales
P/E Ratio-1.46
Enterprise Value to Revenue
Price to book0.89

Upcoming events

Next earnings dayAugust 30, 2022
Next dividend day
Ex. dividend day

News

I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross

I-Mab Sponsored ADR (IMAB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, IMAB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Zacks Investment Research (June 11, 2025)
Why I-Mab Shares Are Jumping Today

I-Mab (NASDAQ: IMAB) has provided updates on the recent development relating to the Holding Foreign Companies Accountable Act (HFCAA) and its implementation.  I-Mab is not on this list, and it has taken proactive measures in response.

Benzinga (March 15, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free